Genenta Science
BioTech/Drugs - Milan, N/A, it
Genenta Science Employees
Valentina Brambilla
Clinical Trial Administrator & Regulatory Affair Specialist
Genenta Science Senior Management
Genenta Science Details
Cancer Immunotherapy - Our gene therapy science to treat cancerWe develop a gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to target interferon-α expression to tumor-infiltrating monocytes/macrophages. An HIV-derived and genetically disabled viral vector - Lentivirus - delivers the gene into the HSPCs. Interferon is a protein usually produced by the body in response to infections that also exhibits a powerful anti-tumor activity. However, the clinical use of interferon as a drug has been limited by its high toxicity. Thanks to our innovative therapy, using a combination of transcriptional and microRNA-mediated control, tumor-infiltrating monocytes/macrophages become capable to selectively express interferon limited to the tumor area, thus reducing its toxicity. Based on these mechanisms, a population of tumor-infiltrating monocytes/macrophages, TIE2-expressing monocytes (TEMs), are armed with a specific drug.
Genenta Science Technologies
Email Providers
Outlook
Load Balancers
Apache
Domain Name Services
Cloudflare DNS
Fonts
Google Font API
Search Marketing
Adobe Marketing Cloud
CSS and JavaScript Libraries
Amcharts JS Library